The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.

This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications.

If you are a research team striving to create best-in-class DDR therapeutics, this is the specific networking forum that has been curated with you in mind.

What Will We Cover?

• Delve into the progress in PARP, ATR & Wee1 including biomarker understanding with AstraZeneca, Bayer, Repare, Merck KGaA, Atrin Pharma, IMPACT Therapeutics, Onxeo, FoRx & Zentalis

• Optimize pre-clinical development through models, novel methodologies & imaging technologies to revolutionize translation with NCI, XPose Therapeutics, Dana-Farber Cancer Institute & Harvard

• Uncover the therapeutic potential & progress in targeting Polθ, WRN, CHK1, DNA-PK, USP1, PARG, PKMYT1 with Artios Pharma, Harvard, NERx Bio, KSQ Therapeutics, IDEAYA & Repare Therapeutics

• Discover the clinical updates on combination, dosing, scheduling & future directions for this exploding field with Newcastle University, MD Anderson, National Brain Tumor Society, Yale, Breakpoint Therapeutics & Harvard

• Network In Person with your peers, ask your burning questions, build connections, and fully immerse yourself in the world of DDR therapeutics.

• A Virtual Attendance Option, giving you access to the same premium quality content as the in-person event, dedicated virtual networking opportunities, & the ability to engage with our event partners

To know more visit: https://ter.li/uzjvgi